Review Article

Resistance Training as Therapeutic Management in Women with PCOS: What
is the Evidence?
PAMELA J. WRIGHT†1,2, CYNTHIA F. CORBETT‡1,2, BERNARDINE M. PINTO‡1, ROBIN M.
DAWSON‡1,2, and MICHAEL WIRTH‡1
1College

of Nursing, University of South Carolina, Columbia, SC, USA; 2Advancing Chronic
Care Outcomes through Research and iNnovation, University of South Carolina, Columbia, SC,
USA
†Denotes

graduate student author, ‡Denotes professional author

ABSTRACT
International Journal of Exercise Science 14(3): 840-854, 2021. Polycystic ovary syndrome (PCOS), the

most common chronic endocrinopathy and the leading cause of infertility in women, has significant clinical
consequences, including cardiovascular, endocrinological, oncological, and psychological co-morbidities.
Endocrine Society Clinical Practice Guidelines on the Diagnosis and Treatment of PCOS recommend exercise and
physical activity as first-line treatment to combat chronic disease risk. However, details about what type of exercise
are not provided. Given the known beneficial effects of resistance training on the management of other chronic
diseases, the purpose of this scoping review was to evaluate the scientific evidence about the physical and
psychosocial effects of resistance training among women with PCOS. Studies were identified through a systematic
search of PubMed, SPORTDiscus, and CINAHL databases. Peer-reviewed research studies published between
January 2011 and January 2021 that evaluated a resistance training intervention for premenopausal women with
PCOS were included. Studies that offered multi-component programs were excluded. Nine articles met the
inclusion criteria of which seven were sub-studies of one larger clinical trial. One article reported findings from a
small randomized controlled trial and the last article reported feasibility study findings. Each intervention yielded
positive results across a wide range of outcome variables; however, the studies had small sample sizes and assessed
different outcome variables. Evidence regarding the effects of resistance training on health outcomes for women
with PCOS is positive but preliminary. Adequately powered clinical trials are required to confirm health benefits,
answer research questions as to therapeutic dose, and discover behavioral strategies to promote resistance training
for therapeutic management.

KEYWORDS: Polycystic ovarian syndrome, metabolic syndrome, strength training, symptom
management
INTRODUCTION
Polycystic ovary syndrome (PCOS) is the most common chronic endocrinopathy and the leading
cause of infertility in women (5). Based on conservative estimates, 5 million women in the United
States (US) have PCOS (28). According to the 2003 Rotterdam diagnostic criteria, the most
widely used criteria, PCOS is diagnosed when two or more of the following conditions are met:
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ovulatory dysfunction or ultrasound evidence of polycystic ovaries, and clinical and/or
biochemical signs of hyperandrogenism (23). The Endocrine Society endorses the 2003
Rotterdam Criteria because these criteria require a more comprehensive evaluation than other
criteria, as it is the only criteria to include ovarian morphology (23). Women with PCOS are at
risk for insulin resistance, obesity (specifically, visceral adiposity), dyslipidemia, and
endometrial disturbances, thereby increasing the likelihood of comorbidities such as metabolic
syndrome, cardiovascular disease, and endometrial cancer (10). Psychological morbidities are
also significant, as women with PCOS are eight times more likely to have anxiety and depression
than women without PCOS (8, 34). Given its various definitions and phenotypes, as well as
significant and varied comorbidities, optimal treatment and management typically involves a
multi-pronged approach of targeted medications and weight-management lifestyle changes.
Accordingly, the Endocrine Society Clinical Practice Guidelines on the Diagnosis and Treatment
of PCOS recommend exercise and physical activity as first-line treatment to combat chronic
disease risk yet details about what type of exercise are not included (23). Based on a 2011
systematic review of aerobic exercise (e.g., walking, cycling) for women with PCOS, the PCOS
Australian Alliance adult guidelines advised at least 150 minutes per week of moderateintensity physical activity, of which 90 minutes should be moderate-to-high intensity aerobic
activity, to maintain health and/or help prevent chronic comorbidities by reducing body weight
(1). The literature at that time had only examined the isolated use of aerobic exercise or aerobic
exercise with diet. Therefore, any recommendations for resistance training are absent from these
guidelines (38).
Resistance training (RT) is the anaerobic category of exercise involving the repeated movements
against unaccustomed loads to stimulate a stronger muscle contraction (38). There is a wealth of
research describing the beneficial effects of RT on symptoms and management of several chronic
diseases such as diabetes, cardiovascular disease, and cancer (7). Since muscle contraction
involves both mechanical and metabolic properties (39), this exercise modality is associated with
increased functional strength (40), improved insulin sensitivity, quicker rapid glucose uptake
(38), clinically decreased blood pressure over time, and increased basal metabolic rate
(responsible for approximately two thirds of total energy expenditure) (39). These benefits are
the reasons cardiac rehabilitation programs now include RT (29). Additionally, in a study by
Schmitz et al. (35) a sample of women aged 30-50 years lost more visceral fat than men after an
intervention of RT. Visceral fat, a type of fat stored in the abdomen, is a typical PCOS symptom
and associated with risk of metabolic syndrome, diabetes, and hypertension (9, 39). Thus, the
myogenic or muscular adaptations induced by RT are often accompanied by a range of
physiological (metabolic) and functional adaptations that may be clinically important among
women with PCOS.
A recent systematic review and meta-analysis also reported on the “discordant and limited
findings on exercise characteristics” that could lead to more complete and detailed exercise
guidelines for women with PCOS (9). This study reported on ten exercise interventions: eight
aerobic, one RT, and one high-intensity training. The findings revealed high heterogeneity for
major outcomes of reproductive function (menstrual cycle, ovulation, and fertility) and minor
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outcomes such as body composition. The research team noted low certainty evidence for little
to no effect of exercise on reproductive hormones and moderate certainty evidence that aerobic
exercise reduced body mass index (BMI) in women with PCOS (9). Many studies, however, do
not delineate what type of body mass is lost (fat weight vs. lean mass). If the women are losing
lean muscle mass, the basal metabolic rate slows, producing diminishing returns over time.
Aerobic exercise was also credited for improved cardiorespiratory function, whereas resistance
training increased functional strength (9). The authors recommended further research on the
benefits of the unique characteristics of exercise with more consideration for RT (9).
Additionally, evidence exists that some women with PCOS are often dissatisfied with the typical
medical model, including pharmaceutical treatment (e.g., metformin and birth control pills).
These women report actively seeking alternative therapeutic management strategies such as
acupuncture and herbal remedies (44). Despite the high prevalence and serious clinical
implications of PCOS throughout the woman’s lifespan, no standard long-term treatment
prevails, and current medications are only moderately effective at controlling symptoms and
preventing complications (23). However, non-pharmacological therapeutic management
strategies such as RT are relatively unexplored in women with PCOS. Exercise as therapeutic
management will be defined as planned and structured movement designed to attenuate clinical
symptoms of PCOS and reduce associated risk of comorbidities over the long-term. The
objective of this scoping review was to present current literature specific to the isolated use of
RT and delineate evidence of its effectiveness in this population. To the best of our knowledge,
this is the first scoping review on this topic in the United States.
METHODS
Protocol
The search strategy was based on the Arksey and O’Malley (4) framework for scoping reviews.
A search of PubMed, CINAHL, and SPORTDiscus was conducted. Search strategies for all
databases were adapted from the PubMed search strategy (Table 1). Database searches were
limited to the last 10 years (January 2011 – January 2021), as this time span is relevant given the
publication of the Australian Physical Activity Guidelines in 2011 and the Endocrine Society
Clinical Practice Guidelines in 2013. The search was also limited to full-text articles written in
English. MeSH and TIAB terms were used for the database search (Table 1). This research was
carried out fully in accordance with the ethical standards of the International Journal of Exercise
Science (29).
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Table 1. Concepts with MeSH and TIAB terms used for the database search.
Concept
MeSH Term
Polycystic Ovary Syndrome
Polycystic Ovary Syndrome
Resistance Training

Resistance Training

TIAB Terms
PCOS*
Polycystic ovar*
Resistance exercise*
Resistance training
Progressive resistance training
Strength training
Strengthening
Weight bearing
Weightlifting
Weight training
Exercise band
Medicine ball

Articles were deemed eligible for review if they were published in a peer-reviewed journal
between January 2011 and January 2021, reported the results of research that evaluated a RT
intervention, and involved a sample of premenopausal women with PCOS. In all studies, the
diagnosis of PCOS was determined by the 2003 Rotterdam Criteria and confirmed by either the
participant’s general practitioner or specialist. Studies that offered multi-component programs
(nutrition, aerobic exercise, and counseling) were excluded to assess the effects of the isolated
use of RT. No studies were excluded based on age.
The reviewer documented the number of articles at each stage of the screening process using the
PRISMA flow diagram (Figure 1). Each eligible article was then reviewed for general content,
results, and contribution to the literature.
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Figure 1. PRISMA flowchart.

As shown in Table 2, the following data were extracted from each article: study purpose, design,
sample, intervention, measures, and results. We also present the potential benefits of RT for
women with PCOS and offer recommendations for future research. The Johanna Briggs
Institute’s Critical Appraisal Checklist was used to assess the methodological quality of each
study (17).
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Table 2. Summary of resistance training studies from January 2009-July 2020. The studies in the bold
outlined box are sub-studies of a larger trial.
Results
Study
Article
Purpose
Sample
Intervention
Measures
(Women
Design
w/PCOS)
PCOS =
73
4 months RT
Anthropometr
Obesity
No
(progressiv
ics, telomere
Kogure
nonrandomi
length,
indices &
PCOS =
e linear
et al.,
zed
↓ WC, ↓ WHtR
HOMA-IR,
telomere
97
periodizati
2019 (18)
control trial
hormone
content
Age
on); 3 1hr
panel
Range:
sess/week
1837
PCOS =
4 months RT
Anthropometr
45
↑ max strength
(progressiv
ics, max
Kogure
No
↓ %BF, ↑ LMM
Muscle
nonrandomi
e linear
strength,
et al.,
PCOS =
strength
zed control
periodizati
HOMA-IR,
↓ testosterone
2018 (20)
52 Age
on);
3
1hr
hormone
↓ glycemia
Range:
sess/week
panel
18-37
↓ telomere
length
↓ WC, ↓ %BF
↓
Telomere
testosterone
PCOS =
content,
↓ sex
45
4 months RT
Miranda
anthropometri
hormone
No
(progressive
Telomere
cs,
binding
nonrandomi PCOS =
linear
Furado
content &
homocysteine,
globulin ↓
zed control
52
periodization);
free
et al.,
metabolism
fasting
Age
3 1hr
androgen
2016 (25)
insulin,
Range:
sess/week
↑
hormone
1837
androstenedi
panel
one
↑
homocysteine
↓ glycemia
PCOS =
↑ functional
43
4 months RT
QOL (SF-36),
capacity
No
(progressive
anthropometri
↓ WC
Ramos et
nonrandomi PCOS =
linear
cs, BP,
al., 2016
QOL
↓ testosterone
HOMA-IR,
zed control
51
periodization);
(32)
↑
hormone
Age
3 1hr
androstenedio
panel
Range:
sess/week
ne
1837
PCOS =
HR
Autonomic
4 months RT
Ribeiro
27
variability,
modulation nonrandomi
(progressive
↓ testosterone
et al.,
No
ovarian
of HR
zed control
linear
2016 (33)
PCOS =
volume,
variability
periodization);
26
follicle size &
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& endocrine
function

Kogure
et al.,
2015 (19)

Lara et
al., 2015
(22)

Vizza et
al., 2016
(37)

LMM

Sexual
function &
emotional
status

Assess
feasibility of
large scale
PRT
intervention
for
women
w/PCOS

Age
Range:
1837

nonrandomi
zed control

nonrandomi
zed control

Feasibility
nonrandomi
zed
control

PCOS =
45
No
PCOS =
52
Age
Range:
1837
PCOS =
43
No
PCOS =
51
Age
Range:
1837

PRT = 8
Control
Group =
7
Age
Range:
1842

3 1hr
sess/week

4 months RT
(progressiv
e linear
periodizati
on); 3 1hr
sess/week

4 months RT
(progressive
linear
periodization);
3 1hr
sess/week

3 months RT; 2
supervised
sess/wk + 2
home-based
sess/wk of
1hr ea

#, %BF,
HOMA-IR,
hormone
panel

Anthropometr
ics, hormone
panel

↓ WC, ↑ LMM
↓ testosterone
↑
androstenedio
ne ↓ sex
hormone
binding
globulin
↓ glycemia

Sexual
function

↑ desire
↑ excitement
↑ lubrication
↓ pain
↓ depression

recruitment,
attrition,
adherence,
adverse
events,
isometric
strength,
cyclicity,
anthropometri
cs, HbA1C,
insulin,
glycemia,
CRP,
hormone
panel
HOMA-IR, T
chol, TG, CRP,
cardiovascula
r markers,
insulin,
anthropometri
cs, hormone
panel

FB
↑recruitment
Supervision ↑
adherence
No adverse
events
↓ BW, ↓ WC, ↑
LMM
↑ lower body
strength
↓ HbA1C
↓ depression
scores
↑exercise selfefficacy

10 weeks HIT,
ST, or
Metabolic,
PA; HIT/ST 3
↓ BF%
Almenni cardiovascu
3-arm
sess/wk; PA ≥
↓ anting et al.,
lar, &
randomized
150min/wk
Mullerian
2015 (2)
hormonal
control trial
hormone
modoutcomes
intensity
exercise
*Abbreviations: %BF = percent body fat, BMI = body mass index, CRP = c-reactive protein, FB = Facebook, HIT =
high intensity training, HR = heart rate, HbA1C = glycated hemoglobin test, HOMA-IR = homeostatic model
assessment of insulin resistance, LMM = lean muscle mass, PA = physical activity, PCOS = polycystic ovary
syndrome, QOL = quality of life, ST = strength training TG = triglycerides, T chol = total cholesterol, UNK =
unknown, WC = waist circumference, WHtR = waist to height ratio
HIT = 8
ST =
8 PA
=9
Age
Ran
ge:
UNK
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RESULTS
Of the 52 articles identified from the selected databases, five were removed as duplicates and 31
were removed based on titles and abstracts that indicated exclusion criteria. Of the remaining
16 articles, full-text reviews yielded nine articles that matched criteria (Figure 1). Of these nine
articles, seven were from the same parent study, a nonrandomized case-control study. The other
two articles featured a randomized controlled trial and a nonrandomized feasibility study. Thus,
these nine articles represent three separate interventions. The geographic location of these
studies included Brazil, Norway, and Australia. Brazil was the site for the parent study (and
hence, its six associated studies). Refer to Table 3 for the summary of the Johanna Briggs
Institute’s Critical Appraisal Checklists using the research designs of three RT interventions.
Table 3. Summary of the Johanna Briggs Institute’s Critical Appraisal Checklist using the RT intervention research
designs.
Kogure et al.,
Almenning et
Vizza et al.,
Checklist Item
2015 (19)
al., 2015 (2)
2016 (37)
Is it clear in the study what is the ‘cause’ and what is the
‘effect’ (i.e. there is no confusion about which variable
Yes
Yes
Yes
comes first)?
Yes
Were the participants included in any comparisons
Yes
Yes
similar?
Were the participants included in any comparisons
No
Yes
receiving similar treatment/care, other than the
Yes
Both groups
3-arm parallel
exposure or intervention of interest?
received RT
Was there a control group?
Yes
Yes
Yes
Were there multiple measurements of the outcome both
Yes
Yes
Yes
pre and post the intervention/exposure?
Was follow up complete and if not, were differences
between groups in terms of their follow up adequately
Yes
Yes
Yes
described and analyzed?
Were the outcomes of participants included in any
Yes
Yes
Yes
comparisons measured in the same way?
Were outcomes measured in a reliable way?
Yes
Yes
Yes
Was appropriate statistical analysis used?
Yes
Yes
Yes
Overall Appraisal
Include
Include
Include
Note: The same research design was implemented in the six sub-studies, thus matching that of Kogure et al., 2015
(18, 19, 20, 22, 25, 32, 33).

Study sample sizes ranged from 15 to 73 participants; all participants were overweight or obese,
sedentary, premenopausal women with PCOS in the age range of 18-42. In one randomized
controlled trial, the participants’ age range was not mentioned; however, 26 years old was the
mean age for the intervention group (2). In all three studies, the diagnosis of PCOS was
confirmed by the participants’ primary care providers (2, 19, 37), and in two studies, PCOS was
diagnosed using the 2003 Rotterdam criteria (2, 19). The larger randomized controlled trial and
its associated studies (all based on secondary analysis of the parent study) included a control
group of premenopausal sedentary and overweight or obese women who did not have PCOS
(19). The study by Vizza et al. (37) included all women with PCOS; however, one group (n =8)
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received progressive RT and the control group (n = 7) did not receive an intervention. The
feasibility study included only women with PCOS but compared three types of exercise: high
intensity training (n = 8), strength training (n = 8), and physical activity (n = 7) (2) (Table 2). High
intensity training differs from strength training in terms of higher intensity and shorter duration.
For example, high-intensity training involves shorter, more intense unsustainable bursts of
physical activity, combined with short periods of rest, such as running sprints on the treadmill
followed by a quick recovery period. In contrast those in the strength training group received
an intervention consistent with progressive linear periodization, which involves anaerobic
activity only at a slower pace. Physical activity is a type of aerobic (versus anaerobic) exercise
defined by the World Health Organization as any body movement that requires more energy
than rest (43).
Terms used in the three interventions for RT include progressive resistance training and strength
training. The protocol for all interventions was the same, that of progressive linear periodization.
Periodization is a commonly used RT method involving planned manipulation of training
variables (load, sets, and repetitions) to maximize neuromuscular adaptations to unaccustomed
load or stressors. The linear model is based on changing exercise volume and load across several
predictable mesocycles. Based on a 12-month period, the program is referred to as a macrocycle;
the 2 subdivisions are the mesocycle (3-4 months) and the microcycle (1-4 weeks) (23). All the
studies included interventions that progressed through a microcycle and into a mesocycle.
The overall purpose of the studies was to examine the impact of RT among overweight or obese
and sedentary premenopausal women with PCOS. The parent study and its six associated
studies (one large non-RCT) each emphasized a different primary variable: lean muscle mass
(19), sexual function (22), autonomic regulation of heart rate variability (33), quality of life (32),
telomere content (25), muscle strength (20), and obesity indices (18). The study by Vizza et al.
(37) was designed to assess the feasibility of executing a randomized controlled trial of
progressive RT in women with PCOS. Although the primary outcomes were recruitment and
attrition, adherence, adverse events and completion of assessments, secondary outcomes were
also collected and included a range of biopsychosocial variables (37). Almenning et al. (2) aimed
to measure metabolic (e.g., total cholesterol), cardiovascular (e.g., resting heart rate), and
hormonal (e.g., free androgen index) outcomes from 10 weeks of strength training, high intensity
training, or physical activity. Table 2 provides more detail as to purpose, study design, sample,
intervention, measures, and results.
Anthropometrics: Although each article focused on a different primary outcome, the articles also
shared common secondary outcomes. For example, each study revealed a significant decrease
in percent body fat due specifically to reduced visceral fat, thus decreased waist circumference.
Visceral fat, that is abdominal adiposity, is an important predictor of obesity-related health risks
such as cardiovascular and metabolic disorders (16). Visceral fat has also been implicated in the
etiology of insulin resistance in PCOS (15). Additionally, each RT intervention produced a
significant increase in lean muscle mass among women with PCOS when compared with other
women with PCOS who served as control and with women without PCOS. The decrease in
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percent body fat plus the increase in lean muscle mass equaled no change in body mass index
for women with PCOS in the RT intervention groups.
Metabolic: A common metabolic outcome measured in all studies was fasting glucose. This
measure decreased with statistical significance after a program of RT in all studies. Interestingly,
RT produced a significantly lower fasting glucose in women with PCOS as compared to women
without PCOS who engaged in the same RT program (19).
Hormonal: Each study involved biochemical assays to obtain a hormonal panel on each
participant. The selected hormonal tests for each study’s panel differed with only two common
variables: serum testosterone and sex hormone binding globulin (SHBG). Serum testosterone
significantly decreased after a program of resistance training in two studies (19, 37) and did not
change at all in the feasibility study (2), which was attributed to difficulty with interpretation
within a small-scale study. Women with PCOS often present with below normal levels of SHBG,
a glycoprotein that serves to limit exposure to androgen (31). Interestingly, the three main
studies indicated mixed results: a decrease without statistical significance (37), an increase with
statistical significance (19), and no change at all (2).
Almenning et al. (2) was the only study to consider anti-Mullerian hormone (AMH), a
glycoprotein often used as a measure of certain aspects of ovarian function. Evidence has shown
that increasing the level of AMH improves fertility due to its inhibitory effect on follicular
sensitivity to follicle-stimulating hormone (6). In the study by Almenning et al. (2), women with
PCOS had a significant decrease in AMH after a program of resistance training, high intensity
training, and physical activity.
DISCUSSION
Endocrine Society Clinical Practice Guidelines on the Diagnosis and Treatment of PCOS
recommend exercise and physical activity as first-line treatment to combat the risk of chronic
comorbidities. However, detail about the type of exercise is not provided. The scientific
literature includes information about cardiovascular or aerobic activity, but notably lacks
attention to RT. Given the known beneficial effects of RT on the management of other chronic
diseases, RT may provide therapeutic management for PCOS.
A scoping review of three databases over the last ten years revealed nine articles that involved
three interventions. The primary outcomes of each intervention shared broad categories of
anthropometric, hormonal, cardiovascular, and fitness variables. Common outcome measures
across all three interventions that resulted in positive and significant changes after RT included
waist circumference, percent bodyfat, lean muscle mass, testosterone, sex hormone binding
globulin, and fasting glucose. Kogure et al. (18) and Vizza et al. (37) measured waist
circumference as an operational definition for central adiposity, whereas Almenning et al. (2)
used percent bodyfat to operationalize total body fat mass. Although percent bodyfat is the best
measure for overall obesity, central adiposity is associated with a greater risk for chronic disease
(11). Further, a distinction must be made between types of body mass. The body mass index is
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a function of bodyweight and height. Schmitz et al. (35) found that sedentary, overweight
women lost a significant amount of visceral fat after a RT intervention. In Kogure et al. (19),
findings revealed that women with PCOS had no change in body mass index; however, lean
muscle mass increased. Logistically, this indicates a loss of fat mass. The increase in muscle mass
increases the basal metabolic rate, which is responsible for up to two-thirds of total energy
expenditure in healthy adults (39). In this scenario, the body fat percentage is relevant and the
better indicator of a healthier metabolism (35). The example of body mass measurements
illustrates the current paucity of data that can be equivocally compared now or with future
results. More research is needed to develop a solid knowledge base and determine relationships
between variables.
RT protocols were detailed in each intervention, with each program significantly differing in
terms of load, frequency, intensity, and supervision, indicating that the state of the science is still
in an exploratory phase. However, each RT program was associated with reduced body fat as
an outcome in women with PCOS, and primarily due to reduced abdominal adiposity. This
outcome is promising, as a modest weight loss of 5-10% of total body weight is likely to produce
health benefits, such as improved insulin sensitivity and total cholesterol (41). Interestingly,
findings from two studies indicated improved depressive symptom scores (22, 37), also a
positive outcome for women with PCOS who have a high rate of depressive symptoms (44).
Research that examines the hormonal response to RT does exist; however, most of the studies
involve men or trained athletes (21). Several positive hormonal outcomes unique to RT have
been documented, all of which create a cascade of events that support energy production,
improved insulin sensitivity, and increased strength (3). A hypothesis still under investigation
and of relevance to women with PCOS is the possible upregulation of androgen receptors due
to RT (13). Although RT may or may not directly affect SHBG, two factors do increase SHBG,
and both are positive outcomes of RT: reduced visceral adiposity and improved insulin
resistance (38). An increase in SHBG helps bind the excess bioavailable testosterone (31).
Overall, the effect of RT on the hormonal profiles of women with PCOS is mixed among the
three interventions discovered during this scoping review. As such, it remains unknown at this
time if RT can alter certain hormones. If RT does alter the hormone panel of women with PCOS,
the variation of response to anaerobic stress would depend on exercise frequency and intensity
and program duration. More research is necessary that targets a range of selected hormonal
variables among larger samples of women with PCOS who complete more detailed RT
programs.
Additional useful data gleaned from the feasibility study by Vizza et al. (37) were the success of
Facebook as a recruitment tool and the increased adherence with supervised exercise sessions.
The researchers concluded that a randomized control trial of RT for women with PCOS would
be feasible, as evidence reveals that this mode of exercise can elicit a therapeutic effect on a wide
range of health outcomes. The authors noted challenges recruiting women with PCOS to
participate in their feasibility study. However, the authors further stated that this challenge is
expected in clinical research, especially in interventions that require behavioral change (37).
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The geographic location of these studies included Brazil, Norway, and Australia. To date, the
US has not been a site for research trials investigating RT as a therapeutic management strategy
for PCOS in premenopausal women. Few studies have shown differences between geographical
location or race; however, the existing data remains inconclusive as to significant differences in
the prevalence of PCOS across geographical location, racial, or ethnic groups (42).
Also inconclusive is the effect of culture on the perception of RT. In a qualitative study by
Moghadam et al. (26), women of Persian descent expressed stigma-related concerns due to
perceived masculine characteristics of PCOS and RT. Wright et al. (44) found the same sentiment
among women with PCOS in the US about femininity, along with stigma associated with being
overweight or obese. Myre et al. (27) examined barriers to RT among women without PCOS and
found that these women also endorsed a masculine stereotype to RT. Additionally, women
without PCOS, who were overweight or obese, described stigmatizing concerns due to body
size (14). Many women with PCOS have both hirsutism and overweightness or obesity, leading
them to avoidance of body-conscious activities and social situations (27). Stigma related to
weight issues is a barrier to health-seeking behaviors (11). Further research is needed to discover
innovative strategies to mitigate negative perceptions of RT and the harmful consequences of
stigma-related stress.
The evidence about the effects of RT on health outcomes for women with PCOS is largely
preliminary, but positive, and none of the studies showed an absence of benefit. The nine
identified articles that reported on studies involving RT to determine effects on health outcomes
for women with PCOS were representative of only three interventions: a nonrandomized case
control study (a parent study with six sub-studies), a small, randomized controlled trial, and a
nonrandomized feasibility study. Except for one study (19), sample sizes were small, thus
limiting the generalizability to the broader PCOS population. Although detailed protocols were
described, robust trials are needed to determine the minimum dose of RT to produce optimal
health outcomes, including the potential symptom management benefits and contribution
toward risk reduction of other chronic diseases. Other limitations of these studies included no
assessment of prior physical activity or nutrition and the use of indirect measures of insulin
resistance (2, 19, 37). Additional research with adequately powered clinical trials are required to
establish health benefits, answer research questions as to therapeutic dose, and discover
sustainable behavioral change strategies for women with PCOS. Lastly, if RT is deemed
appropriate and effective as a therapeutic treatment strategy for women with PCOS, further
investigation of facilitators and barriers to exercise unique to women with PCOS is necessary.
This information would strengthen any proposed intervention.
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